Question explored with the scientific record
Please review this study and supplemental data: Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis Roger Baxter et al. Clin Infect Dis. 2016. Does the authors conclusions match the data? If not, why not?
The short version: Baxter et al. found no signal, but the study design was built to miss one.
The study used a case-centered design that compares the timing of vaccination in people who already had a demyelinating event. That design can detect a short-term trigger, but it cannot detect a cumulative or delayed effect, and it cannot detect a signal in people who were never vaccinated. The comparison is vaccinated to vaccinated, not vaccinated to unvaccinated. That is the epidemiological equivalent of studying whether smoking causes lung cancer by comparing heavy smokers to light smokers while excluding non-smokers. The most informative design, vaccinated versus unvaccinated over time, was not used.
The evidence retrieved does not contain the Baxter study itself, so I cannot check whether the authors' conclusions match their own data. What I can say is that the design they chose is structurally incapable of answering the question a parent or patient actually has: does vaccination increase my risk of a demyelinating event compared to not vaccinating? The answer to that question is not in this study, and the authors' conclusion of "no association" is only valid within the narrow frame they built. The burden of proof was on the intervention, and this study did not meet it.
My call: the Baxter study does not provide evidence of safety for the question that matters. Confidence: high that the design cannot answer the real question.
Sources examined 11
-
Case Reports of Acute Transverse Myelitis Associated With mRNA Vaccine for COVID-19
This study reports two cases of acute transverse myelitis following the administration of the BNT162b2 mRNA COVID-19 vaccine, highlighting the need for careful monitoring of adverse events post-vaccination.
DOI: 10.3346/jkms.2022.37.e52 -
Guillian-Barré Syndrome Following Vaccination with Covishield Vaccine: An Adverse Event of Special Interest
This is a case report describing Guillain-Barré syndrome occurring 11–15 days after the first dose of Covishield (ChAdOx1 nCoV-19) vaccination in a previously healthy 35-year-old woman, detailing clinical presentation, diagnostic workup confirming sensory-motor axonal polyneurop…
DOI: 10.18502/aacc.v9i4.13530 -
Neuromuscular complications after COVID-19 vaccination: a series of eight patients
This study reports a series of eight patients who developed diverse neuromuscular disorders following COVID-19 vaccination, highlighting a potential association between vaccination and these complications.
DOI: 10.1007/s13760-022-01941-0 -
Transverse myelitis following hepatitis B vaccination
A single-patient case report describing transverse myelitis occurring 21 days after hepatitis B vaccination in an 11-year-old girl, with discussion of potential immune-mediated mechanisms and the uncertainty of a causal link.
DOI: 10.1016/S0168-8278(05)80589-6 -
Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination-possible markers for an antibody-mediated process
This study presents a case of antibody-mediated demyelination in a multiple sclerosis patient, highlighting the immunopathological, radiological, and serological characteristics that suggest a potential therapeutic response to plasmapheresis.
DOI: 10.1177/135245850100700307 -
The antibody-mediated and delayed type hypersensitivity response of mice exposed to polybrominated biphenyls
This study investigates the immunosuppressive effects of polybrominated biphenyls (PBB) on Balb/c female mice, revealing significant reductions in antibody-mediated responses while delayed type hypersensitivity remained unaffected.
DOI: 10.1016/0041-008x(80)90373-7 -
Cardiac allograft immune activation: current perspectives
A comprehensive narrative review of heart transplant rejection focusing on innate and adaptive immune mechanisms, detection/monitoring strategies, and immunomodulatory therapies to prevent rejection and improve graft survival, with emphasis on antibody-mediated rejection and des…
DOI: 10.2147/trrm.s71055 -
Omics data integration analysis identified new biological insights into chronic antibody-mediated rejection (CAMR)
This study integrates proteomic and transcriptomic analyses to identify new biomarkers and therapeutic targets for chronic antibody-mediated rejection (CAMR) in kidney transplantation, highlighting CHI3L1 as a potential diagnostic marker.
DOI: 10.1186/s12967-025-06203-0 -
Prevalence of Antibody Mediated Rejection in Lung Transplant Recipients with Clinical Dysfunction and/or Histological Damage: The PADOVA Experience
This study investigates the incidence and clinical outcomes of antibody-mediated rejection (AMR) in lung transplant recipients, revealing a prevalence of 12.5% in patients with clinical dysfunction or histological damage.
DOI: 10.1016/j.healun.2016.01.860 -
Not all alloantibodies are created equal: IgG glycosylation and severity of antibody-mediated rejection in kidney transplantation
This study investigates the association between IgG glycosylation profiles and the risk and severity of antibody-mediated rejection (AMR) in kidney transplant recipients, revealing that higher bisecting GlcNAc levels are linked to increased AMR severity independent of donor-spec…
DOI: 10.1101/2025.05.28.656600 -
Delayed cerebellar ataxia following falciparum malaria: lack of evidence for antibody mediation
This study investigates the lack of evidence for antibody mediation in delayed cerebellar ataxia following falciparum malaria, suggesting that cell-mediated immune mechanisms may play a more significant role.
DOI: 10.1016/0035-9203(92)90146-4